Drugs / Nexlizet
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | NEXLIZET | — | 2020-02-26 | fda.gov ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06280976 | Mar 2024 → Jan 2025 | atherosclerosis, coronary artery disorder, myocardial infarction | University of Louisville | Withdrawn | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nexlizet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06280976 ↗ |